Hepatocellular Carcinoma Patient Outcomes for TACE, Lenvatinib, and PD-1 Inhibitor Therapy

190 patient records from a retrospective single-center study conducted between February 2022 and February 2025. The data compares clinical outcomes for HBV-positive and HBV-negative patients with unresectable hepatocellular carcinoma undergoing triple therapy. Author Yuhao Su published the dataset under a CC-BY-4.0 license on figshare in April 2026.

Use Cases

• Associating hepatitis B virus infection status with surgical conversion rates based on patient stratification.
• Comparing overall survival and progression-free survival between patient groups based on the study's primary endpoints.
• Analyzing tumor response rates (ORR, DCR) according to mRECIST criteria mentioned in the description.
• Evaluating treatment-related adverse events for safety profile comparisons between cohorts.

Strengths

• Dataset includes 190 patient records with a clear temporal coverage from February 2022 to February 2025.
• Analysis employs propensity score matching (1:1) to balance baseline characteristics between 30 matched pairs.
• Clinical endpoints are clearly defined, including surgical conversion, OS, PFS, and tumor response with specific P-values reported.

Limitations

• Row count for the underlying data is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center retrospective study, which may limit generalizability.

Provenance

Source

figshare, author Yuhao Su.

Collection Method

Retrospective single-center cohort study of consecutive patients.

Time Range

February 2022 to February 2025.

Freshness

Last updated 2026-04-23 05:35:34; freshness should be verified.